Martien Wampers

A cross-sectional evaluation of adiponectin plasma levels in patients with schizophrenia and schizoaffective disorder (2008)

Van Winkel, Ruud, Wampers, Martien, Van Eyck, Dominique, Scheen, Andre, Reginster, Jean-Yves, ...

BACKGROUND: In recent years, several studies showed increased rates of hyperglycaemia, diabetes, dyslipidemia, metabolic syndrome as well as cardiovascular disease in schizophrenic patients. The...

The incidence of dysglycemia and metabolic syndrome varies according to the psychiatric diagnosis of bipolar disorder, schizophrenia and schizoaffective disorder (2008)

Scheen, Andre J, Van Winkel, Ruud, Celic, Ivan, Hanssens, Linda, Wampers, Martien, ...

Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder (2008)

Wampers, Martien, Van Eyck, Dominique, Hanssens, Linda, Scheen, Andre, ...

OBJECTIVE: To investigate 3-month changes in glucose metabolism in a naturalistic sample of patients with schizophrenia newly started on or switched to specific atypical antipsychotic medication...

Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder (2008)

Van Eyck, Dominique, Hanssens, Linda, Wampers, Martien, Scheen, Andre, ...

OBJECTIVES: The presence of metabolic abnormalities is an important risk factor for cardiovascular disease and diabetes. There are limited data on the prevalence of the metabolic abnormalities in...

Psychiatric diagnosis as an independent risk factor for metabolic disturbances: results from a comprehensive, naturalistic screening program. (2008)

Van Winkel, Ruud, Van Os, Jim, Celic, Ivan, Van Eyck, Dominique, Wampers, Martien, Scheen, André, ...

OBJECTIVE: Unconfounded differences in inherent vulnerability to metabolic disturbance may be hypothesized for different diagnostic groups with severe mental illness. METHOD: A naturalistic cohort of...

Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder. (2008)

Van Winkel, Ruud, De Hert, Marc, Wampers, Martien, Van Eyck, Dominique, Hanssens, Linda, Scheen, André, ...

OBJECTIVE: To investigate 3-month changes in glucose metabolism in a naturalistic sample of patients with schizophrenia newly started on or switched to specific atypical antipsychotic medication...

Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. (2008)

De Hert, Marc, Schreurs, Vincent, Sweers, Kim, Van Eyck, Dominique, Hanssens, Linda, Sinko, Sebastjan, ...

The presence of the metabolic syndrome (MetS) is an important risk factor for cardiovascular disease and diabetes. There are limited data on the prevalence of MetS in patients with schizophrenia at...

A cross-sectional evaluation of adiponectin plasma levels in patients with schizophrenia and schizoaffective disorder. (2008)

Hanssens, Linda, Van Winkel, Ruud, Wampers, Martien, Van Eyck, Dominique, Scheen, André, Reginster, Jean-Yves, ...

BACKGROUND: In recent years, several studies showed increased rates of hyperglycaemia, diabetes, dyslipidemia, metabolic syndrome as well as cardiovascular disease in schizophrenic patients. The...

Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder. (2008)

Van Winkel, Ruud, De Hert, Marc, Van Eyck, Dominique, Hanssens, Linda, Wampers, Martien, Scheen, André, ...

OBJECTIVES: The presence of metabolic abnormalities is an important risk factor for cardiovascular disease and diabetes. There are limited data on the prevalence of the metabolic abnormalities in...

A cross-sectional evaluation of adiponectin plasma levels in patients with schizophrenia and schizoaffective disorder. (2008)

Hanssens, Linda, Van Winkel, Ruud, Wampers, Martien, Van Eyck, Dominique, Scheen, André, Reginster, Jean-Yves, ...

BACKGROUND: In recent years, several studies showed increased rates of hyperglycaemia, diabetes, dyslipidemia, metabolic syndrome as well as cardiovascular disease in schizophrenic patients. The...

Anticholinergic use in hospitalised schizophrenic patients in Belgium (2007)

Wampers, Martien, Van Winkel, Ruud

This naturalistic study aims to evaluate the influence of antipsychotic treatment on the use of anticholinergics. The observed use of anticholinergics will give an indication of the occurrence of...

Glucose dysregulation in schizophrenic patients receiving second generation antipsychotics: A3-month prospective comparative study (2007)

Scheen, Andre J, Hanssens, Linda, Wampers, Martien, Van Winkel, Ruud, Van Eyck, Dominique, ...

A Case Series: Evaluation of the Metabolic Safety of Aripiprazole (2007)

De Hert, Marc, Hanssens, Linda, Van Winkel, Ruud, Wampers, Martien, Van Eyck, Dominique, Scheen, Andre, ...

Metabolic abnormalities occur frequently in patients treated with antipsychotics and are of growing concern to clinicians. This study sought to determine whether antipsychotic-associated metabolic...

A Case Series: Evaluation of the Metabolic Safety of Aripiprazole (2007)

Hanssens, Linda, Van Winkel, Ruud, Wampers, Martien, Van Eyck, Dominique, Scheen, Andre, ...

Metabolic abnormalities occur frequently in patients treated with antipsychotics and are of growing concern to clinicians. This study sought to determine whether antipsychotic-associated metabolic...

Pharmacological treatment of severe dyslipidaemia in patients with schizophrenia (2007)

Kalnicka, Dita, Van Winkel, Ruud, Wampers, Martien, Van Eyck, Dominique, ...

Mortality rates in patients with schizophrenia are double compared with the general population, with cardiovascular disease causing 50% of the excess. Lowering low-density lipoprotein cholesterol is...

Treatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia and schizoaffective disorder (2006)

Kalnicka, Dita, Van Winkel, Ruud, Wampers, Martien, Hanssens, Linda, Van Eyck, Dominique, ...

BACKGROUND: Mortality rates in patients with schizophrenia are double compared to those in the general population, with cardiovascular disease causing 50% of the excess. Lowering low-density...

Screening for diabetes and other metabolic abnormalities in patients with schizophrenia and schizoaffective disorder: evaluation of incidence and screening methods (2006)

Van Eyck, Dominique, Hanssens, Linda, Wampers, Martien, Scheen, Andre, ...

OBJECTIVE: To assess the diagnostic properties of 2 different screening guidelines for the detection of diabetes in patients diagnosed with schizophrenia. METHOD: Over a 2-year period (November...

Reversibility of antipsychotic treatment-related diabetes in patients with schizophrenia: a case series of switching to aripiprazole (2006)

Hanssens, Linda, Van Winkel, Ruud, Wampers, Martien, Van Eyck, Dominique, Scheen, Andre, ...

Oral glucose tolerance tests in treated patients with schizophrenia. Data to support an adaptation of the proposed guidelines for monitoring of patients on second generation antipsychotics? (2006)

Van Eyck, Dominique, Hanssens, Linda, Peuskens, Hendrik, Thys, Erik, Wampers, Martien, ...

OBJECTIVE: A recent consensus conference has proposed guidelines for the monitoring for diabetes in patients with schizophrenia and also identifies the need of long-term prospective studies. METHOD:...

Usefulness of glycosylated haemoglobin (HbA1c) to screen for diabetes in patients with schizophrenia (2006)

Van Eyck, Dominique, Wampers, Martien, Scheen, Andre

Oral glucose tolerance tests in treated patients with schizophrenia. Data to support an adaptation of the proposed guidelines for monitoring of patients on second generation antipsychotics? (2006)

De Hert, Marc, Van Eyck, Dominique, Hanssens, Linda, Peuskens, Hendrik, Thys, Erik, Wampers, Martien, ...

Objective. - A recent consensus conference has proposed guidelines for the monitoring for diabetes in patients with schizophrenia and also identifies the need of long-term prospective studies....

Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication (2006)

De Hert, Marc A., Van Winkel, Ruud, Van Eyck, Dominique, Hanssens, Linda, Wampers, Martien, Scheen, André, ...

The presence of the metabolic syndrome is an important risk factor for cardiovascular disease and diabetes. There are limited data on the prevalence of the metabolic syndrome in European patients...

Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication (2006)

Van Winkel, Ruud, Van Eyck, Dominique, Hanssens, Linda, Wampers, Martien, Scheen, Andre, ...

The presence of the metabolic syndrome is an important risk factor for cardiovascular disease and diabetes. There are limited data on the prevalence of the metabolic syndrome in European patients...

Treatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia and schizoaffective disorder. (2006)

De Hert, Marc, Kalnicka, Dita, Van Winkel, Ruud, Wampers, Martien, Hanssens, Linda, Van Eyck, Dominique, ...

BACKGROUND: Mortality rates in patients with schizophrenia are double compared to those in the general population, with cardiovascular disease causing 50% of the excess. Lowering low-density...

Screening for diabetes and other metabolic abnormalities in patients with schizophrenia and schizoaffective disorder: evaluation of incidence and screening methods. (2006)

Van Winkel, Ruud, De Hert, Marc, Van Eyck, Dominique, Hanssens, Linda, Wampers, Martien, Scheen, André, ...

OBJECTIVE: To assess the diagnostic properties of 2 different screening guidelines for the detection of diabetes in patients diagnosed with schizophrenia. METHOD: Over a 2-year period (November...

Usefulness of glycosylated haemoglobin (HbA1c) to screen for diabetes in patients with schizophrenia. (2006)

Hanssens, Linda, De Hert, Marc, Van Eyck, Dominique, Wampers, Martien, Scheen, André, Peuskens, Joseph

A Case Series: Evaluation of the Metabolic Safety of Aripiprazole (2006)

De Hert, Marc, Hanssens, Linda, Van Winkel, Ruud, Wampers, Martien, Van Eyck, Dominique, Scheen, Andre, ...

Metabolic abnormalities occur frequently in patients treated with antipsychotics and are of growing concern to clinicians. This study sought to determine whether antipsychotic-associated metabolic...

Oral glucose tolerance tests in schizophrenic patients treated with antipsychotics (2004)

De Hert, Marc, Van Eyck, Dominique, Hermans, Gilberte, Peuskens, Hendrik, Wampers, Martien, De Patoul, A, ...

Objective. –A recent consensus conference has proposed guidelines for the monitoring for diabetes in patients with schizophrenia and also identifies the need of long-term prospective studies....

A Case Series: Evaluation of the Metabolic Safety of Aripiprazole

De Hert, Marc, Hanssens, Linda, Van Winkel, Ruud, Wampers, Martien, Van Eyck, Dominique, Scheen, Andre, ...

Metabolic abnormalities occur frequently in patients treated with antipsychotics and are of growing concern to clinicians. This study sought to determine whether antipsychotic-associated metabolic...